#United States #Nashville #Inflammatory Bowel Disease #Skyrizi #RINVOQ

AbbVie Presents Promising New Data for IBD Treatments

AbbVie recently unveiled significant findings regarding their leading immunology therapies, SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib), at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting. This meeting, held in Nashville, Tennessee, from October 9 to October 14, emphasized the company's commitment to addressing the complexities faced by patients suffering from inflammatory bowel disease (IBD).

The Impact of New Research Findings

The latest Phase 3 AFFIRM data showcased that patients treated with subcutaneous SKYRIZI exhibited higher rates of both clinical and endoscopic responses compared to those receiving a placebo. This was particularly evident in individuals with moderate to severe Crohn's disease. Notably, the efficacy was maintained across various patient demographics and clinical scenarios, signifying the treatment's broad applicability.

Furthermore, open-label extension studies demonstrated that patients experienced sustained improvement over time when treated with SKYRIZI, even those with challenging disease profiles and prior therapies. These findings are crucial, given that IBD often presents complex treatment challenges and can greatly diminish patients' quality of life.

A Commitment to Patient Needs

Dr. Ryan DeMasi, Vice President of Global Medical Affairs at AbbVie, stated, “Individuals living with IBD desire treatments that significantly alleviate their condition’s burdens.” This sentiment underscores AbbVie’s ongoing mission to develop therapies that not only mitigate symptoms but also enhance patients’ overall well-being over time.

RINVOQ's Role in Disease Management

The presentation also highlighted RINVOQ's role in managing advanced Crohn's disease, particularly in patients who have previously faced difficulties with their treatment options. Notably, real-world data from studies within the Veterans Affairs healthcare system showed that a remarkable 93.3% of patients with fistulizing disease achieved clinical remission while on RINVOQ treatment.

Such data reinforces the potential of RINVOQ as a beneficial option for those suffering from complex and hard-to-treat forms of IBD, ensuring that patients have access to effective treatment methodologies.

Highlights from the Conference

Among the numerous presentations at the ACG conference, several key studies provided insights into the effectiveness of these medications:

• - Efficacy of SKYRIZI in Crohn's Disease: An analysis demonstrated that patients experienced enhanced clinical and endoscopic outcomes through 144 weeks of treatment. Notably, remission rates showed improvement across various disease locations, emphasizing SKYRIZI’s versatility in treating different manifestations of Crohn's disease.
• - Long-term Benefits of RINVOQ: An analysis revealed that RINVOQ produced impressive remission rates among patients with stricturing disease, indicating the drug's effectiveness in real-world scenarios where traditional treatments may have failed.

Conclusion

AbbVie's robust portfolio for IBD care exemplifies their commitment to adhering to patient-centric treatment insights. As they continue to conduct crucial research, developments in therapies like SKYRIZI and RINVOQ could reshape the management landscape for patients battling chronic inflammatory conditions. The findings reflect the hopeful narrative of progress and possibility in the treatment of IBD, paving the way for enhanced relief and remission for many patients in need.